SCHEMBL17454440

SCHEMBL17454440

CC(=O)c1cnn2cc(CCCN3CCC(F)(F)C3)ccc12

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNC P24863 3/20 0.36
CDK8 P49336 3/20 0.36
GRM4 Q14833 1/20 0.36
GRM2 Q14416 2/20 0.35
KIF11 P52732 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
GLS O94925 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
FGFR3 P22607 1/20 0.33
KDR P35968 1/20 0.33
MAPK14 Q16539 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KCNA3 P22001 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17454520 0.94 NOS3 (0.38) CCNCCDK8GRM4GRM2HTR2A
SCHEMBL19902424 0.91 CCNC (0.35) CCNCCDK8GRM4GRM2KIF11
SCHEMBL17452720 0.91 HTR2A (0.35) CCNCCDK8GRM4GRM2KIF11
SCHEMBL17452719 0.84 HTR2A (0.38) GRM4GRM2HTR2AHTR2CHRH3
SCHEMBL17454474 0.83 SIGMAR1 (0.42) HTR2AHTR2CHRH3
SCHEMBL17453654 0.80 HRH3 (0.42) HTR2AHTR2CHRH3
SCHEMBL17454444 0.76 IRAK4 (0.39)
SCHEMBL17452717 0.75 SIGMAR1 (0.39) HTR2AHTR2CHRH3
SCHEMBL17454406 0.74 HDAC4 (0.41)
SCHEMBL19675627 0.73 SIGMAR1 (0.41) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 CCNC 1995/4885CDK8 1196/4885GRM4 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.